HomeCLLS • NASDAQ
add
Cellectis SA
Previous close
$3.24
Day range
$3.00 - $3.27
Year range
$0.96 - $3.77
Market cap
219.06M USD
Avg Volume
67.64K
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 1.99M | -88.51% |
Operating expense | 31.40M | 40.87% |
Net income | -42.86M | -59.84% |
Net profit margin | -2.15K | -1,291.39% |
Earnings per share | -0.57 | 3.39% |
EBITDA | -18.45M | -496.60% |
Effective tax rate | -0.01% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 136.71M | 52.25% |
Total assets | 334.27M | 27.97% |
Total liabilities | 249.58M | 84.49% |
Total equity | 84.70M | — |
Shares outstanding | 65.30M | — |
Price to book | 2.49 | — |
Return on assets | -27.19% | — |
Return on capital | -42.23% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -42.86M | -59.84% |
Cash from operations | 39.72M | — |
Cash from investing | -13.65M | — |
Cash from financing | 41.58M | — |
Net change in cash | 69.35M | — |
Free cash flow | 4.78M | — |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
235